← Eichor
Study identifier: NCT05422508 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

Condition: Varicella  ·  Sponsor: Green Cross Corporation

PhasePhase 2
Planned participants230
Who can joinAll sexes, 4 Years to 6 Years
Healthy volunteersYes

About this study

* Primary objective is to assess the safety of MG1111 until Day 42 using as 2nd vaccination * Secondary objective to assess the immunogenicity and safety of MG1111 using as 2nd vaccination

This description comes directly from the study's public registry record.

Talk to the study team

Hye Won Shin  ·  +82-31-260-9032  ·  hwshin27@gccorp.com

Always discuss trial participation with your own doctor first.

Locations (1)

Korea University Ansan HospitalAnsan, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05422508